A Randomized Phase I Trial Evaluating Safety and Pharmacokinetics of Single and Multiple Ascending Doses of Eclitasertib, a RIPK1 Inhibitor, in Healthy ParticipantsChristine Farenc, Yong Lin|Advances in Therapy|2025Cited by 1